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Skeletal dysplasias represent a large and diverse group of rare conditions affecting
collagen and bone. They can be clinically classified based on radiographic and physical
features, and many can be further defined at a molecular level (Bonafe et al., 2015). Early
diagnosis is critical to proper medical management including pharmacologic treatment
when available. Patients with severe skeletal dysplasias often have small chests with
respiratory insufficiency or airway obstruction and require immediate intubation after birth.
Thereafter a variety of orthopedic, neurosurgical, pulmonary, otolaryngology interventions
may be needed. In terms of definitive treatment for skeletal dysplasias, there are few
pharmacotherapeutic options available for the majority of these conditions. We sought
to describe therapies that are currently available or under investigation for skeletal
dysplasias.
Keywords: hypophosphatasia, mucopolysaccharidosis, osteogenesis imperfecta, achondroplasia, Asfotase alfa,
enzyme replacement therapy
INTRODUCTION
A skeletal dysplasia is diagnosed in 1 of 5,000 births each year (Orioli et al., 1986). Severity is highly
variable and can range from mild short stature to perinatal lethality. Among patients with less
severe forms that allow survival are many who will require significant care for the duration of their
lives. Despite research in the area of skeletal dysplasias that has elucidated a great deal about the
genetic pathophysiology of these conditions, there remain limited therapeutic options.
The ability to accurately diagnose a skeletal dysplasia in utero has improved in recent years due
to advances in prenatal ultrasound and molecular diagnosis. There are, however, limitations to
ultrasound; certain skeletal dysplasias may not be seen until the third trimester (e.g., some forms
of osteogenesis imperfecta), while others may manifest as late as infancy or early childhood (e.g.,
pseudoachondroplasia). In general, the earlier the dysplasia manifests, the more significant are its
effects in terms of prenatal and postnatal morbidity and mortality. When sonographic findings are
present, parents benefit from prenatal counseling and anticipatory guidance. Understanding the
inheritance pattern is also important to direct recurrence risk estimates for future pregnancies,
particularly when both parents are affected with a skeletal dysplasia. Inheritance depends on
the specific dysplasia and may include autosomal dominant, autosomal recessive and X-linked
inheritance, or a combination of these when both parents are affected.
Medical management of patients with skeletal dysplasias is dictated by the underlying
pathogenesis along with the type and severity of physical manifestations in the realm of
orthopedics, neurosurgery, otolaryngology, and pulmonary services. Pharmacologic treatment for
these conditions is disease-specific (Table 1), and 4 conditions/groups will be discussed.
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TABLE 1 | Therapeutic options for skeletal dysplasias.
Clinical therapy Investigational/other therapy
Osteogenesis Imperfecta Bisphosphonates, growth
hormone, Teriparatide
In utero stem cell transplantation, Raloxifene, Denosumab, Sclerastin, Anti-TGFβ
Hypophosphatasia Asfotase alfa Human parathyroid hormone*, bone marrow transplant*,
gene therapy*
Mucopolysaccharidosis (MPS) Stem cell transplantation, chaperone therapy, gene therapy
MPS Type I Laronidase Bone marrow transplant
MPS Type II Idursulfase
MPS Type IVa Elosulfase alfa
MPS Type VI Galsulfase
Achondroplasia C-type natriuretic peptides, meclozine, human parathyroid hormone, human growth hormone
*No longer employed, or under investigation.
OSTEOGENESIS IMPERFECTA
Osteogenesis imperfecta (OI), also known as “brittle bone
disease,” is characterized by short stature, bone deformation,
bone fragility, and osteoporosis (Forlino et al., 2011). There are
over a dozen types of OI with a prevalence of 1–2 per 20,000
children (Yap and Savarirayan, 2016). Pathogenic mutations
in OI have been uncovered in the following genes: COL1A1,
COL1A2, SERPINF1, CRTAP, LEPRE1, PPIB, SERPINHI, or
FKBP10. The majority of cases are due to an autosomal dominant
mutation in COL1A1 and COL1A2 resulting in types I–IV,
classified based on severity (Yap and Savarirayan, 2016). These
mutations affect formation of type I collagen, which is the most
prominent connective tissue in bone and skin.
Type I patients have a quantitative deficiency of collagen and
often have blue sclerae and fractures without deformity. Patients
with Types II–IV have defective forms of collagen caused by
improper formation of the triple helix resulting in continual
remodeling with a dominant negative effect. Type II OI is
perinatally lethal, due to severe intrauterine fractures and bone
deformities (Harrington et al., 2014). Type III is the most severe
nonlethal type of OI, presenting with normal mental capacity
(Krakow, 2015) and progressive deformities resulting in loss of
ambulatory abilities (Krakow, 2015). Type IV OI is milder than
type III, but still severe, commonly characterized by vertebral
fractures and short stature (Krakow, 2015). Types II and III are
generally detectable in utero (Krakow et al., 2008; Krakow, 2015),
whereas the milder types of OI, types I, IV, and V, are usually
diagnosed after birth (Harrington et al., 2014). Patients with type
II and type III OI likely have a small chest cavity, and may require
mechanical ventilation if demise is not inevitable secondary to
severe fractures (Harrington et al., 2014).
In addition to the autosomal dominant mutations in COL1A1
and COL1A2, 5–10% of cases are due to a mutation in
another gene. Type V OI, due to an autosomal dominant
mutation in IFTITM5, is recognized by hypercallus formation
and calcification of the intraosseous membrane (Liu et al., 2016).
An autosomal recessive mutation in SERPINF1 is responsible
for type VI (Harrington et al., 2014). Additional types of OI are
autosomal recessive and are not well-recognized because they
are very rare. Examples include the following types and (genes):
type VII (CRTAP), type VIII (LEPRE1), type IX (PPIB), type
X (SERPINH1), and Type XI (FKBP10; Harrington et al., 2014;
Krakow, 2015).
Of the skeletal dysplasias, osteogenesis Imperfecta currently
has the most pharmacologic treatment options. Overall the goal
is to improve bone density and decrease fractures, and there are
several drug families currently employed to do this (Lee et al.,
2016). Medications include bisphosphonates, growth hormones,
denosumab, and teriparatide. Additional therapies are under
investigation; Raloxifine improves outcomes in murine models,
and mesenchymal bone marrow transplant has promise when
initiated in utero.
Bisphosphonates
Bisphosphonates are one of the major pharmacotherapeutic
agents clinically prescribed for OI (Dwan et al., 2014; Harrington
et al., 2014). Bisphosphonates suppress bone remodeling and
inhibit calcification by inactivating osteoclasts (Dwan et al.,
2014; Harrington et al., 2014), which, in turn, decreases areal
bone mineral density (aBMD), primarily in the spine, hip, and
femur and decreases the incidence of fractures (Ward et al.,
2010). There is variation in fracture incidence, aBMD, and bone
pain among these agents (alendronate, pamidronate, etc.; Dwan
et al., 2014) and in their route of administration (intravenous vs.
oral). Adverse side effects to long-term use of bisphosphonates
have been found, including cumulative micro damage, cartilage
calcification (Sinder et al., 2013; Vasanwala et al., 2016), and
osteonecrosis of the jaw in elderly patients (Dwan et al., 2014;
Harrington et al., 2014). Bisphosphonates have been found to
be less effective after 2–4 years of treatment, so intermittent
treatment may be more beneficial in some cases.
Growth Hormone
Osteogenesis imperfecta is not typically associated with growth
hormone deficiency, but growth hormone treatment can be
beneficial by increasing aBMD and growth velocity in children
with OI (Antoniazzi et al., 2010). In a randomized study,
recombinant growth hormone (rGH) was combined with
bisphosphonate therapy (Antoniazzi et al., 2010). Although, the
rate of fractures did not differ, lumbar spine and wrist bone
mineral density increased. There was no apparent decrease in
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fracture rate overall (Harrington et al., 2014), yet the combination
of rGH and bisphosphonates has not been shown to increase
fracture rate either (Antoniazzi et al., 2010).
Teriparatide
Teriparatide is a bone stimulating recombinant form of
parathyroid hormone used in anabolic therapy to treat
osteoporosis (Vahle et al., 2002; Orwoll et al., 2014). When given
in concert with bisphosphonate therapy, teriparatide has been
shown to increase aBMD (Orwoll et al., 2014) and accelerate the
healing of fractures (Rozen et al., 2007) in adults with Type I
OI. In more severe forms of OI (types III and IV), teriparatide
treatment showed no increase in aBMD compared to control
groups (Orwoll et al., 2014).
Future OI Therapies
Development of OI treatments is ongoing. Studies have
demonstrated an increase in bone healing by callus formation
when teriparatide is combined with BMP-7, a recombinant
protein in bones (Morgan et al., 2008). Raloxifene has been shown
to decrease the rate of bone fractures in mice (Berman et al.,
2016) and may prove to be useful to decrease fractures in future
human trials of OI. Denosumab is an antibody currently used to
prevent fractures in post-menopausal women with osteoporosis
(Cummings et al., 2009; Shaker et al., 2015) and is being evaluated
to treat OI. Sclerostin antibody has been shown in studies to
increase bone formation, therefore improving bone mass (Sinder
et al., 2013; Shaker et al., 2015), which is essential to OI
preventative measures. Anti-TGFβ therapy may also prove to be
beneficial in decreasing osteoblast signaling and bone resorption
(Shaker et al., 2015) in future OI treatment.
There are presently no clinically available in utero therapies
for any of the skeletal dysplasias, however bone marrow and
mesenchymal stem cell transplantation are currently under study
for in utero treatment of OI (Mehrotra et al., 2010; Harrington
et al., 2014). Case series demonstrate safety, with transient
improvements in bone growth and decreases in fractures (Chan
and Götherström, 2014). A larger clinical trial is underway
(Chitty et al., 2016).
HYPOPHOSPHATASIA
Hypophosphatasia (HPP) is a rare metabolic disorder resulting
from a loss-of-function mutation in the ALPL gene with
corresponding deficiency of tissue-nonspecific alkaline
phosphatase (TNSALP) (Millán and Plotkin, 2012; Whyte
et al., 2015; Yap and Savarirayan, 2016). There are 6 recognized
clinical forms of HPP with varied severity, all correlated
to insufficient mineralization of bone and teeth as well as
osteomalacia in adults (Yap and Savarirayan, 2016). Although,
mild forms of HPP are found in adolescents and adults, HPP
that manifests in the fetus is almost always associated with
infantile and perinatal lethality (Millán and Plotkin, 2012; Yap
and Savarirayan, 2016) due to abnormal skeletal development
and respiratory complications resulting from a small chest with
pulmonary hypoplasia (Nishioka et al., 2006).
Current Treatments for HPP
Asfotase alfa is a human recombinant TSNALP currently used
to safely treat HPP by reestablishing TSNALP levels for proper
degradation of inorganic pyrophosphate and consequential
regulated bone mineralization (Nishioka et al., 2006;Whyte et al.,
2016; Yap and Savarirayan, 2016). One study of this subcutaneous
form of enzyme replacement therapy has demonstrated increased
strength and agility as a result of improved bone mineralization
(Whyte et al., 2016). An immense increase in perinatal and
postnatal survival rates has been observed in patients treated with
asfotase alfa (Whyte et al., 2016). In an open label study, infants
with a previously perinatal lethal condition whowere treated with
asfotase alfa survived to have average stature with mainly defects
in tooth enamel (Whyte et al., 2012).
Potential Treatments for HPP
Prior to the availability of asfotase alfa, several treatments were
under investigation for HPP. These included bone marrow
transplants (Millán and Plotkin, 2012), parathyroid hormone
(PTH) treatment (Millán and Plotkin, 2012), and fetal gene
therapy. Although, fetal gene therapy appeared to improve
postnatal development in murine models (Sugano et al., 2011),
its potential benefits are no longer under investigation due to the
dramatic clinical benefits of enzyme replacement therapy with
asfotase alfa.
MUCOPOLYSACCHARIDOSIS
Mucopolysaccharidoses (MPSs) are a type of lysosomal storage
disease, a rare group of disorders that results in symptoms
secondary to a defect in lysosomal function leading to abnormal
storage of glycosaminoglycans (GAGs) in the bones, heart,
brain, liver, or spleen (Muenzer, 2014; Regier and Tanpaiboon,
2016). The enzyme deficiency is specific to the type of MPS.
MPSs are progressive, so most cases become lethal as the
patient ages (Walkley, 2009) as GAG builds up and causes
multiple organ failures (Muenzer, 2011). GAGs are also involved
in complex secondary signaling pathways which can create
permanent cellular damage (Muenzer, 2014), so early diagnosis
and treatment are essential to patient longevity (Clarke, 2011).
Early diagnosis, however, is often difficult in patients with normal
cognitive abilities (Muenzer, 2011; Lachman et al., 2014; Regier
and Tanpaiboon, 2016). There are seven types of MPS, each
of which is caused by an autosomal recessive disorder, except
for MPS II, which is X-linked recessive and generally occurs
only in males (Valayannopoulos and Wijbug, 2011; Muenzer,
2014). Current treatments for the mucopolysaccharidoses
are focused mostly on enzyme replacement therapy (ERT)
and hematopoietic stem cell transplantation (HSCT; Clarke,
2011).
Enzyme replacement therapy (ERT) involves intravenous
administration of the deficient enzyme specific to each type of
MPS (Valayannopoulos and Wijbug, 2011; Haneef and Doss,
2016). ERT is currently used to treat MPS I, MPS II, and MPS VI
(Muenzer, 2014; Haneef and Doss, 2016). Its use in the treatment
of MPS IV type A (Morquio) is under observational study now
that it has been FDA approved (Haneef and Doss, 2016; Regier
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and Tanpaiboon, 2016). Although, repeated administration
ERT may improve some of the symptoms of MPS including
respiratory function and mobility, it cannot reverse existing
skeletal disease (Muenzer, 2014).
MPS I is caused by deficiency of α-L-iduronidase (IDUA;
Wang et al., 2009; Valayannopoulos and Wijbug, 2011; Ou
et al., 2016), a critical enzyme in the GAG degradation pathway
of heparin sulfate and dermatan sulfate (Kakkis et al., 2001;
Muenzer, 2011; Regier and Tanpaiboon, 2016). MPS I is
categorized into 3 groups based on its presentation and severity:
Hurler’s syndrome (severe; lethal by age 10); Hurler-Scheie
syndrome (moderate; lethality by age 20); and Scheie’s syndrome
(mild; possible normal life span; Kakkis et al., 2001). Larodinase is
used in ERT forMPS I, and has been shown to safely reverse some
MPS symptoms, not including those relating to skeletal disease
(Wraith et al., 2004; Muenzer, 2014).
MPS II is the only form ofMPS that is inherited as an X-linked
recessive disorder. It results from a deficiency of iduronate-
2-sulphatase (Muenzer, 2011) which, similar to MPS I, leads
to insufficient degradation of dermatin sulfate and heparin
sulfate (Muenzer, 2011; Haneef and Doss, 2016; Motas et al.,
2016). Idursulfase administration has resulted in reduced non-
central nervous system symptoms of MPS II (Haneef and Doss,
2016).
MPS IVA and VI are difficult to distinguish because of their
varied presentation (Lachman et al., 2014), however treatment
is dependent on the diagnosis. MPS IVA results from deficiency
of N-acetylgalactosamine-6-sulfatase (GALNS) corresponding to
the buildup of keratan sulfate (KS) and chondroitin-6-sulfate
(C6S) (Regier and Tanpaiboon, 2016). Clinical treatment forMPS
IVA with elsosulfase alfa is underway (Regier and Tanpaiboon,
2016). Galsulfase is currently the only treatment for MPS VI
and has been successful in improving pulmonary function and
mobility (Motas et al., 2016).
Hematopoietic stem cell transplantation (HSCT) and bone
marrow transplantation are used to introduce unaffected donor
cells into the body and correct the lysosomal disorder by
the accompanied addition of the enzyme that was previously
lacking (Haneef and Doss, 2016). HCST is recommended in
treating Hurler syndrome (MPS I) with ERT pre-treatment
for the best results (Clarke, 2011; Muenzer, 2014). HSCT has
been less successful in patients with MPS II or severe forms
of MPS III (Muenzer, 2014; Motas et al., 2016). Bone marrow
transplant was effective in reversing CNS symptoms (Walkley
et al., 1994) in MPS I, MPS II, MPS VI, and MPS VII but
is associated with a high complication rate (Haneef and Doss,
2016).
Future Therapies for MPS
Chaperone therapy could potentially treat MPS by assisting in the
proper folding of proteins to create functional enzymes that break
down GAG (Kakkis et al., 2001). Gene therapy is promising in
finding a cure for skeletal dysplasias if the mutated gene can be
correctly identified and modified to produce functional proteins,
but development of this technique will take continued research
(Kakkis et al., 2001).
ACHONDROPLASIA
Achondroplasia (ACH) is an autosomal dominant disorder
generally resulting from a specific gain-of-function mutation
(G380R) in the fibroblast growth factor receptor 3 (FGFR3)
(Wang et al., 2013; Krakow, 2015; Yap and Savarirayan, 2016). As
the most common type of nonlethal skeletal dysplasia, occurring
in 1–2 of every 20,000 live births (Savarirayan and Rimoin,
2002; Yasoda et al., 2009; Klag and Horton, 2016), ACH is the
cause for most cases of dwarfism (Klag and Horton, 2016; Yap
and Savarirayan, 2016). The common clinical presentation of
ACH includes short stature, relative macrocephaly with frontal
bossing (Matsushita et al., 2014), and rhizomelic limb shortening
(Faruqi et al., 2014; Krakow, 2015). There are usually no cognitive
impairments associated with ACH unless symptoms result due to
a complication of another manifestation (Gordon, 2000). Severe
symptoms may result due to spinal stenosis at the foramen
magnum.
Abnormal long-bone development typically is not obvious
until after the first half of the second trimester thus, early prenatal
diagnosis of ACH by ultrasound is not common (Krakow
et al., 2008; Krakow, 2015). When achondroplasia is suspected,
prenatal molecular diagnosis can be employed to evaluate for
the specific G380R mutation, however sequencing of FGFR3may
be preferred if hypochodroplasia is on the list of differential
diagnoses. Affected parents may also desire prenatal molecular
diagnosis or pre-implantation genetic diagnosis to evaluate for a
known maternal or paternal mutation (Wang et al., 2013).
Pharmacologic treatments for ACH are currently in stage
2 clinical trials (Wendt et al., 2015; Klag and Horton, 2016).
Treatments are aimed at regulating the function of FGFR3
in growth plate formation (Matsushita et al., 2014). FGFR3
negatively regulates bone growth (Faruqi et al., 2014). Its elevated
function leads to irregular endochondral ossification (Wendt
et al., 2015; Yap and Savarirayan, 2016) and underdeveloped
linear bone growth (Liu et al., 2016) resulting from interrupted
differentiation of chondrocytes (Yasoda et al., 2009; Wendt et al.,
2015; Klag and Horton, 2016).
C-type natriuretic peptides (CNP) increased linear bone
growth in murine models with ACH by antagonizing FGFR3
signals (Wang et al., 2013; Faruqi et al., 2014; Klag and Horton,
2016). Most CNPs are active in the body for less than 3min (Klag
and Horton, 2016) before they are removed by the natriuretic
clearance receptor (NPR C) and neutral endopeptidase (NEP)
(Wendt et al., 2015). Constant intravenous infusions of these
short-lived CNPs would be required to observe any improvement
of endochondral ossification in patients (Yasoda et al., 2009;
Wendt et al., 2015). BMN 111 (vosoritide) is a type of CNP
that is resistant to digestion by NEP, and therefore has a
longer circulation period in the body (Klag and Horton, 2016).
Recent studies have shown an increased annual linear bone
growth in cynomolgus monkeys (Wendt et al., 2015) and in
children with ACH after daily subcutaneous administration of
BMN 111 (Klag and Horton, 2016). BMN 111 is the most
promising of CNP treatments and the only treatment for
ACH that has made it to clinical trials (Klag and Horton,
2016).
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Possible Future Treatments of
Achondroplasia
Meclozine is an oral antihistamine that has been shown to
block negative signaling of FGRF3 in chondrocytes (Matsushita
et al., 2014; Klag and Horton, 2016) and increase linear bone
growth in mice, both with ACH and wild-type (Matsushita
et al., 2014). Furthermore, intermittent injection of human
parathyroid hormone [PTH] in mice was accompanied by
increased chondrogenesis and recovered bone growth (Xie et al.,
2012). Human growth hormone (hGH) can increase short-term
bone growth velocity in children, but is an ineffective therapy
in adults (Savarirayan and Rimoin, 2002; Yasoda et al., 2009;
Matsushita et al., 2014). A short-term study found increased
chondrogenesis by statin administration, specifically rosuvastatin
(Yamashita et al., 2014), but long-term analysis has not been
done.
CONCLUSION
The currently available clinical therapies for patients with
skeletal dysplasia are predominantly palliative in nature, however
enzyme replacement therapy is now available for certain skeletal
conditions. The ability to perform enzyme replacement therapy
requires knowledge of the underlying molecular diagnosis as well
as the pathogenic pathway by which the mutation affects bone
growth and/or development. In addition to enzyme replacement
therapy, bone marrow transplant is a less specific form of therapy
that is clinically beneficial for several skeletal dysplasias. It is
also being trialed in utero for osteogenesis imperfecta. A lack
of suitable biomarkers accounts for the deficiency of therapeutic
treatments (Briggs et al., 2015). Identifying these biomarkers
will enable more useful treatment methods, but there is also
associated difficulty with targeting the specific mutations, even
when their identity is known (Tomatsu et al., 2013). Advances in
molecular technology enable a more rapidly confirmed diagnosis
as well as an earlier diagnosis in childhood and even in utero.
This is key to allow for useful therapies specific to the underlying
diagnosis. Our diagnostic capabilities will allow for a more
personalized approach to treatment and targeted gene therapy as
a foreseeable approach in the future.
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